Phyton Biotech Signs Development Agreement With Insmed
31 Juillet 2006 - 5:00PM
PR Newswire (US)
EAST WINDSOR, N.J. and GLEN ALLEN, Va., July 31
/PRNewswire-FirstCall/ -- Phyton Biotech, Inc., a DFB
Pharmaceuticals affiliate, and Insmed Incorporated (NASDAQ:INSM)
have announced an agreement whereby Phyton will utilize its cGMP
plant cell fermentation technology to develop a manufacturing
process that could be utilized to meet the future demand of
IPLEX(TM) (mecasermin rinfabate [rDNA origin] injection) as it
expands with the development of IPLEX(TM) in broader therapeutic
indications. IPLEX(TM) was approved by the FDA in December 2005 for
the treatment of growth failure in children with severe primary
IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene
deletion who have developed neutralizing antibodies to GH. One of
the key attributes of Phyton's cGMP plant cell fermentation
technology is that it can be scaled up to any size needed. Phyton's
German subsidiary, Phyton Biotech GmbH, operates the world's
largest commercial cGMP manufacturing facility for plant cell
fermentation, with bioreactors up to 75,000 liters in size. "The
efficiencies and economies of scale assured by our plant cell
fermentation system provide an excellent solution to meet the
future demand for IPLEX(TM) as its use expands into broader
therapeutic indications," said Magnus Precht, President of New
Jersey-based Phyton Biotech. "We recognize the potential of Phyton
Biotech's technology to help Insmed address the anticipated future
demand for our product," said Insmed CEO Geoffrey Allan, Ph.D. "If
this cutting edge technology proves successful with our product, we
believe it will give Insmed a long-term competitive advantage over
companies utilizing older technologies." "Our ability to
genetically manipulate plant cells and to scale production combine
to offer an advantage in the marketplace," said Mr. Precht, "The
Phyton plant cell fermentation technology has utility not found in
other cell expression systems." "This agreement is an important
step toward DFB's and Phyton's strategic goals of developing and
manufacturing novel pharmaceutical products," said H. Paul Dorman,
CEO and Chairman of DFB Pharmaceuticals. The companies expect that
the development conducted under the agreement will demonstrate the
efficiencies of Phyton's unique plant cell expression technology
and its ability to produce the quantities of IPLEX(TM) needed to
meet the long-term demand for the product. About Phyton Biotech,
Inc. Phyton Biotech, Inc., based in East Windsor, N.J., is a
subsidiary of DFB Pharmaceuticals, Inc. Phyton's proprietary plant
cell culture technology platform is used to develop and manufacture
products with applications in the pharmaceutical and biotech
industries. Phyton is focusing its research and development efforts
on developing transgenic protein therapeutics utilizing Phyton's
broad expertise in plant cell suspension culture technology. Other
current Phyton projects include production of paclitaxel for
Bristol-Myers Squibb's TAXOL(R) oncology product and development of
DiAthegen LLC's protein therapeutics focused in the endocrine and
oncology areas. Phyton is on the web at
http://www.phytonbiotech.com/ . Based in Fort Worth, DFB
Pharmaceuticals, Inc. is a privately held Texas corporation that
provides technology-driven pharmaceutical products, outsourcing
services, and licensing opportunities to the healthcare industry
worldwide through Phyton and its other affiliates, HEALTHPOINT,
Ltd. and Coria Laboratories, Ltd., both branded marketing
organizations; DPT Laboratories, Ltd., an outsourcing service
organization to the pharmaceutical industry; and DFB Bioscience,
focusing on cell based therapeutic research and development. Visit
http://www.dfb.com/ for additional information. About Insmed
Incorporated Insmed, Inc., based in Glen Allen, Virginia, is a
biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs. For more
information, please visit http://www.insmed.com/ . The company's
leading product, IPLEX was approved as an orphan drug by the United
States Food and Drug Administration in December 2005 for the
treatment of growth failure in children with severe primary IGF-I
deficiency (Primary IGFD) or with growth hormone (GH) gene deletion
who have developed neutralizing antibodies to GH. About IPLEX
IPLEX, a complex of recombinant human IGF-I and its binding protein
IGFBP- 3 (rhIGF-I/rhIGFBP-3), is the only once-daily IGF-I
replacement therapy. It is also the only FDA-approved therapy that
provides both rhIGF-I and rhIGFBP-3 to treat children with severe
primary IGFD. The drug, which was launched in May 2006, is also
being investigated for various other indications with unmet medical
needs, including extreme insulin resistance, myotonic muscular
dystrophy and HIV Associated Adipose Redistribution Syndrome
(HARS). DATASOURCE: Phyton Biotech, Inc.; Insmed Incorporated
CONTACT: Magnus Precht of Phyton Biotech, Inc., +1-609-426-2520, or
; or media, Kathy Jeavons of Ketchum Public Relations,
+1-202-835-9473, or ; or investors, Tim Ryan of The Trout Group,
+1-212-477-9007, ext. 24, or , both for Insmed Incorporated Web
site: http://www.phytonbiotech.com/ http://www.dfb.com/
http://www.insmed.com/
Copyright
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024